JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Japan ETF
EWJ
|
+$1.18B |
| 2 |
Vanguard Total International Bond ETF
BNDX
|
+$1.07B |
| 3 |
iShares Core MSCI EAFE ETF
IEFA
|
+$1B |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$963M |
| 5 |
Medtronic
MDT
|
+$799M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.5B |
| 2 |
Microsoft
MSFT
|
+$873M |
| 3 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$716M |
| 4 |
Chubb
CB
|
+$675M |
| 5 |
Lowe's Companies
LOW
|
+$661M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.77% |
| 2 | Technology | 12.5% |
| 3 | Healthcare | 9.29% |
| 4 | Consumer Discretionary | 8.66% |
| 5 | Industrials | 8.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FLXN
2751
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $3.39M | ﹤0.01% |
151,397
-14,774
| -9% | -$361K |
|
2752
Vanguard FTSE All-World ex-US Small-Cap Index Fund
VSS
$12B
| $3.39M | ﹤0.01% |
28,413
-2,705
| -9% | -$327K |
|
|
JNCE
2753
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $3.38M | ﹤0.01% |
151,415
-11,308
| -7% | -$251K |
|
2754
StoneX
SNEX
$8.05B
| $3.38M | ﹤0.01% |
401,021
-661,076
| -62% | -$5.56M |
|
2755
CALL
United Therapeutics
UTHR
$21.5B
| $3.37M | ﹤0.01% |
+30,000
| New | +$3.81M |
|
2756
Varonis Systems
VRNS
$5.26B
| $3.37M | ﹤0.01% |
167,115
-87,822
| -34% | -$1.63M |
|
|
CCEC
2757
Capital Clean Energy Carriers
CCEC
$1.36B
| $3.37M | ﹤0.01% |
154,281
+1,158
| +0.8% | +$26.7K |
|
2758
Perion Network
PERI
$384M
| $3.36M | ﹤0.01% |
1,401,022
| – | – |
|
|
MOBL
2759
DELISTED
MobileIron, Inc.
MOBL
| $3.36M | ﹤0.01% |
678,378
+297,971
| +78% | +$1.36M |
|
|
CNCE
2760
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $3.35M | ﹤0.01% |
146,508
-11,558
| -7% | -$257K |
|
|
MFA
2761
MFA Financial
MFA
$931M
| $3.35M | ﹤0.01% |
111,206
-135,985
| -55% | -$4.04M |
|
2762
PUT
Teva Pharmaceuticals
TEVA
$42.6B
| $3.35M | ﹤0.01% |
195,700
+700
| +0.4% | +$13.7K |
|
|
INFN
2763
DELISTED
Infinera Corporation Common Stock
INFN
| $3.34M | ﹤0.01% |
307,710
-2,602,612
| -89% | -$23.1M |
|
|
SGYP
2764
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $3.34M | ﹤0.01% |
1,826,266
-937,272
| -34% | -$1.98M |
|
2765
CALL
NetEase
NTES
$78.5B
| $3.34M | ﹤0.01% |
59,500
-125,000
| -68% | -$7.85M |
|
2766
Aclaris Therapeutics
ACRS
$863M
| $3.33M | ﹤0.01% |
190,281
+185,266
| +3,694% | +$3.93M |
|
2767
iShares MSCI Intl Momentum Factor ETF
IMTM
$4.33B
| $3.33M | ﹤0.01% |
108,933
+25,618
| +31% | +$800K |
|
2768
Ligand Pharmaceuticals
LGND
$5.76B
| $3.33M | ﹤0.01% |
32,272
-36,885
| -53% | -$3.65M |
|
2769
CALL
Mohawk Industries
MHK
$9.42B
| $3.32M | ﹤0.01% |
14,300
| – | – |
|
|
VRN
2770
DELISTED
Veren
VRN
| $3.32M | ﹤0.01% |
488,306
+278,130
| +132% | +$2.11M |
|
|
ARC
2771
DELISTED
ARC Document Solutions, Inc.
ARC
| $3.32M | ﹤0.01% |
1,508,987
+43,664
| +3% | +$103K |
|
2772
State Street SPDR Portfolio S&P 400 Mid Cap ETF
SPMD
$19.1B
| $3.32M | ﹤0.01% |
+100,000
| New | +$3.37M |
|
2773
Myers Industries
MYE
$1.25B
| $3.31M | ﹤0.01% |
156,543
-17,686
| -10% | -$366K |
|
|
CPE
2774
DELISTED
Callon Petroleum Company
CPE
| $3.31M | ﹤0.01% |
24,994
-2,387
| -9% | -$280K |
|
|
GOLD
2775
DELISTED
Randgold Resources Ltd
GOLD
| $3.31M | ﹤0.01% |
39,737
-5,826
| -13% | -$525K |
|
Similar funds
JP Morgan Chase's Q1 2018 Portfolio in Review
As of Q1 2018, JP Morgan Chase held 5,855 positions worth $467B, down 1.7% from $475B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q1 2018 filing shows 386 new, 1,953 increased, 2,570 reduced and 469 closed positions. Its largest new stake was Avaya Holdings Corp. Common Stock: 9,632,519 shares worth $216M. The largest sale was Apple, an estimated $1.5B.
By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 15% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q1 2018 buy was Avaya Holdings Corp. Common Stock: 9,632,519 shares worth $216M.
- JP Morgan Chase added most to iShares MSCI Japan ETF in Q1 2018, an estimated $1.18B increase.
- JP Morgan Chase's biggest Q1 2018 reduction was Apple, cutting an estimated $1.5B.
- JP Morgan Chase fully exited Scripps Networks Interactive, Inc Common Class A in Q1 2018, selling an estimated $168M.
- JP Morgan Chase's ten largest holdings make up 18% of its $467B portfolio in Q1 2018.
- JP Morgan Chase opened 386 new positions and closed 469 in Q1 2018.
- JP Morgan Chase's portfolio value fell 1.7% quarter-over-quarter to $467B.
Based on JP Morgan Chase's 13F filing for Q1 2018, filed 10 May 2018.